FibroGen, Inc (NASDAQ:FGEN)‘s stock had its “hold” rating reissued by research analysts at Mizuho in a research report issued on Thursday. They currently have a $61.00 price objective on the biopharmaceutical company’s stock. Mizuho’s price objective indicates a potential upside of 29.46% from the company’s previous close.

The analysts wrote, “We believe Fibrogen is fairly priced. KeyPoints Earnings. For 3Q17, Fibrogen’s financials missed street estimates on reported revenue of $27.3 mil vs. consensus of $39.7 mil and missed on reported EPS of $(0.50) vs. consensus of $(0.37). License and milestone revenue recognized in the quarter appeared lower than expectations. R&D and SG&A expenses were approximately in-line with our prior projections. For 4Q17, Fibrogen expects to recognize a $15 mil milestone from AstraZeneca (AZN, not rated) related to roxadustat’s NDA filing in October 2017 in China. Quarterly earnings are usually not a driver for development stage companies like Fibrogen. In our opinion, news flow related to the pipeline development are more likely to be a catalyst. Progress for pamrevlumab in IPF. During the quarter Fibrogen reported positive topline results from their phase II trial for pamrevlumab in moderate- to-severe idiopathic pulmonary fibrosis (IPF) patients.””

Several other equities analysts have also recently issued reports on the stock. Goldman Sachs Group, Inc. (The) cut shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research note on Friday, July 21st. Jefferies Group LLC reissued a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research report on Tuesday, September 12th. Stifel Nicolaus reissued a “buy” rating and issued a $80.00 target price on shares of FibroGen in a research report on Thursday, September 14th. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Citigroup Inc. lifted their target price on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $65.67.

Shares of FibroGen (NASDAQ:FGEN) traded down $1.13 on Thursday, hitting $47.12. 754,500 shares of the stock traded hands, compared to its average volume of 626,675. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.21 and a current ratio of 10.83. FibroGen has a 12 month low of $19.25 and a 12 month high of $60.15.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/11/fibrogen-inc-fgen-stock-rating-reaffirmed-by-mizuho.html.

In other FibroGen news, insider K Peony Yu sold 7,500 shares of FibroGen stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $55.37, for a total value of $415,275.00. Following the completion of the sale, the insider now directly owns 170,104 shares in the company, valued at $9,418,658.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $56.13, for a total transaction of $2,168,638.68. Following the completion of the sale, the chief executive officer now owns 3,144,573 shares of the company’s stock, valued at $176,504,882.49. The disclosure for this sale can be found here. Insiders sold 428,118 shares of company stock valued at $22,355,896 over the last quarter. Corporate insiders own 14.90% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN lifted its stake in shares of FibroGen by 53.5% in the third quarter. Wells Fargo & Company MN now owns 104,733 shares of the biopharmaceutical company’s stock worth $5,634,000 after buying an additional 36,504 shares during the last quarter. Amalgamated Bank lifted its stake in shares of FibroGen by 15.0% in the third quarter. Amalgamated Bank now owns 8,423 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 1,097 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of FibroGen by 31.1% in the third quarter. Legal & General Group Plc now owns 27,967 shares of the biopharmaceutical company’s stock worth $1,500,000 after buying an additional 6,634 shares during the last quarter. Eagle Asset Management Inc. acquired a new stake in shares of FibroGen in the third quarter worth $46,158,000. Finally, TD Asset Management Inc. lifted its stake in shares of FibroGen by 23.7% in the third quarter. TD Asset Management Inc. now owns 31,926 shares of the biopharmaceutical company’s stock worth $1,718,000 after buying an additional 6,126 shares during the last quarter. Institutional investors and hedge funds own 47.47% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.